Table 2. Prevalence of mutations from the WHO transmitted drug resistance surveillance list.
| NRTI mutations | NNRTI mutations | PI mutations | ||||||||
| Mutation | N | (Pv, %) | Mutation | n | (Pv, %) | Mutation | n | (Pv, %) | ||
| M41L | 32 | (1.15) | L100I | 2 | (0.07) | L24I | 2 | (0.07) | ||
| K65R | 1 | (0.04) | K101EP | 8 | (0.29) | D30N | 1 | (0.04) | ||
| D67EGN | 23 | (0.83) | K103N/S | 77 | (2.77) | V32I | 2 | (0.07) | ||
| T69D | 5 | (0.18) | Y181CIV | 9 | (0.32) | M46IL | 26 | (0.93) | ||
| K70ER | 5 | (0.18) | Y188CHL | 5 | (0.18) | I47AV | 2 | (0.07) | ||
| L74IV | 3 | (0.11) | G190AES | 11 | (0.40) | F53LY | 2 | (0.07) | ||
| F77L | 2 | (0.07) | P225H | 3 | (0.11) | I54ALMSTV | 2 | (0.07) | ||
| Y115F | 2 | (0.07) | M230L | 1 | (0.04) | V82ACFLMST | 5 | (0.18) | ||
| M184IV | 13 | (0.47) | N83D | 1 | (0.04) | |||||
| L210W | 12 | (0.43) | I85V | 1 | (0.04) | |||||
| T215REV* | 37 | (1.33) | N88DS | 2 | (0.07) | |||||
| T215YF | 2 | (0.07) | L90M | 10 | (0.36) | |||||
| K219EQNR | 29 | (1.04) | ||||||||
| 1 mut. | 56 | (2.01) | 1 mut. | 87 | (3.13) | 1 mut. | 45 | (1.62) | ||
| 2 mut. | 32 | (1.15) | 2 mut. | 13 | (0.47) | 2 mut. | 2 | (0.07) | ||
| ≥3 mut. | 13 | (0.47) | ≥3 mut. | 2 | (0.07) | ≥3 mut. | 1 | (0.04) | ||
| Prevalence (95%CI) | 3.6 | (2.9–4.3) | Prevalence (95%CI) | 3.7 | (3.0–4.4) | Prevalence (95%CI) | 1.7 | (1.2–2.2) | ||
NRTI: nucleoside reverse transcriptase inhibitors; NNRTI: non-nucleoside reverse transcriptase inhibitors; PI: protease inhibitors; Pv: prevalence; mut.:mutation. Amino acide abbreviations: A, alanine; C, cysteine; D, aspartate; E, glutamate; F, phenylalanine; G, glycine; H, histidine; I, isoleucine; K, lysine; L, leucine; M methionine; N, asparagine; P, proline; Q, glutamine; R, arginine; S, serine; T, threonine; V, valine; W, tryptophan; Y, tyrosine. * = C/D/E/N/I/V/S.